An in vitro study of blast cell metabolism in acute myeloid leukaemia using the MTT assay

Leukemia Research

Volumn 20, Issue 5, 1996, Pages 407-413

  Elgie, Alena W ^a   Sargent, Jean M ^a   Taylor, Colin G ^a   Williamson, Christine ^a  

^a Pembury Hospital   (United Kingdom)

Author keywords

AML; Cell metabolism; Drug resistance; MTT assay

Indexed keywords

CYTARABINE; CYTOTOXIC AGENT; ETOPOSIDE; FORMAZAN; GLYCOPROTEIN P; TIOGUANINE;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; ASSAY; BLAST CELL; BONE MARROW; CELL METABOLISM; CELL PROLIFERATION; CELL SIZE; CELL SURVIVAL; CONTROLLED STUDY; DRUG SENSITIVITY; HUMAN; HUMAN CELL; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MONONUCLEAR CELL; MYELODYSPLASTIC SYNDROME; OPTICAL DENSITY; PRIORITY JOURNAL; SURVIVAL TIME; TREATMENT FAILURE;

EID: 0029937384     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/0145-2126(95)00163-8     Document Type: Article

References (32)

1. Raza A., Preisler H. D., Day R., Yasin Z., White M., Lykins J., et al. (1990) Direct relationship between remission duration in acute myeloid leukaemia and cell cycle kinetics: a leukaemia intergroup study. Blood 76, 2191.
2. Raza A., Preisler H., Lampkin B., Yousef N., Tucker C., Peters N., et al. (1991) Biological significance of cell cycle kinetics in 128 standard risk newly diagnosed patients with acute myelocytic leukaemia. Br. J. Haemat. 79, 33.
3. Giordano M., Danova M., Mazzini G., Gobbi P. & Riccardi A. (1992) Cell kinetics with in vivo bromodeoxyuridine assay, proliferating cell nuclear antigen expression, and flow cytometric analysis. Prognostic significance in acute non lymphoblastic leukaemia. Cancer 71, 2739.
4. Barnes M. & Gillett C. E. (1995) Determination of cell proliferation. J. clin. Pathol: Molec. Pathol. 48, M2.
5. Mosmann T. (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxic assays. J. immun. Meth. 65, 55.
6. Pieters R., Huismans D. R., Leyva A. & Veerman A. J. P. (1988) Adaptation of the rapid automated tetrazolium dye based (MTT) assay for chemosensitivity testing in childhood leukaemia. Cancer Lett. 41, 323.
7. Denizot F. & Lang R. (1986) Rapid colorimetric assay for cell growth and survival. Modifications to the terazolium dye procedure giving improved sensitivity and reliability. J. immun. Meth. 89, 271.
8. Page M., Bejaoui N., Cing-Mars B. & Lemieux P. (1988) Optimization of the tetrazolium based colorimetric assay for the measurement of cell number and cytotoxicity. Int. J. Immunopharmac. 10, 785.
9. Gerlier D. & Thomasset N. (1986) Use of the MTT colorimetric assay to measure cell activation. J. immun. Meth. 94, 57.
10. Slater T. F., Sawyer B. & Strauli U. (1963) Studies on succinate-tetrazolium reductase systems. III. Points of coupling of four different tetrazolium salts. Biochim. biophys. Acta 77, 383.
11. Berridge M. V. & Tan A. S. (1993) Characterization of the cellular reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT): subcellular localization, substrate dependence, and involvement of mitochondrial electron transport. Arch. Biochem. Biophys. 303, 474.
12. Pieters R., Huismans D. R., Leyva A. & Veerman A. J. P. (1989) Comparison of the rapid automated MTT-assay with a dye exclusion assay for chemosensitivity testing in childhood leukaemia. Br. J. Cancer 59, 217.
13. Sargent J. M. & Taylor C. G. (1989) Appraisal of the MTT assay as a rapid test of chemosensitivity in acute myeloid leukaemia. Br. J. Cancer 60, 206.
14. Wilson J. K., Sargent J. M., Elgie A. W., Hill J. G. & Taylor C. G. (1990) A feasibility study of the MTT assay for chemosensitivity testing in ovarian malignancy. Br. J. Cancer 62, 189.
15. Sargent J., Elgie A., Alton P., Williamson C. & Taylor C. (1995) Identification of drug resistance in fresh blast cells from acute myeloid leukaemia and its modification in vitro. In Contributions to Oncology (Zeller W. J., D'Incalci M., Newell D. R., Eds), Vol. 49, pp. 109-116. Karger, Basel.
16. Pieters R., Huismans D. R., Loonen A. H., Hahlen K., Van Der Does-Van Den Berg A., Van Wering E. R. & Veerman A. J. P. (1991) Relation of cellular drug resistance to long term clinical outcome in childhood acute lymphoblastic leukaemia. Lancet 338, 399.
17. Langkjer S. T. & Nørgaard J. M. (1993) In Drug Resistance in Leukaemia and Lymphoma. The Clinical Value of Laboratory Studies (Kaspers G. J. L., Pieters R., Twentyman P. R., Weisenthal L. M. & Veerman A. J. P., Eds), p. 279. Harwood Academic, Chur, Switzerland.
18. Pirker R., Wallner J., Geiddler K., et al. (1991) MDR1 gene expression and treatment outcome in acute myeloid leukaemia. J. natn. Cancer Inst. 83, 708.
19. Zhou D. C., Marie J. P., Suberville A. M. & Zittoun R. (1991) Relevance of mdr1 gene expression in acute myeloid leukaemia and comparison of different diagnostic methods. Leukaemia 6, 879.
20. Kato S., Ideguchi H., Muta K., Nishimura J. & Nawata H. (1991) Absence of correlation between cytotoxicity and drug transport by P-glycoprotein in clinical leukaemic cells. Eur. J. Haemat. 47, 146.
21. Ito Y., Tanimoto M., Kumazawa T., Okumuru M., et al. (1989) Increased P-glycoprotein expression and multidrug resistant gene (mdr-1) amplification are infrequently found in fresh acute leukaemia cells. Cancer 63, 1534.
22. Faulkner-Pulsford J. F., Sargent J. M., Elgie A. W. & Taylor C. G. (1995) Comparison of P-glycoprotein expression with in vitro drug sensitivity in fresh blast cells from acute myeloid leukaemia patients. J. biomed. Sci. 52, 188.
23. Rees J. K. H., Gray R. G., Swirsky D. & Hayhoe F. G. J. (1986) Principle results of the Medical Research Council 8th Acute Myeloid Leukaemia Trial. Lancet ii, 1236.
24. Gorst D., Clough V., Taylor P., Proctor S., Gilbert M. & Ross J. (1994) Leukaemia survival in an unselected cohort of 2304 patients. The four regions leukaemia register. Br. J. Haemat. 86 (Suppl. 1), 45.
25. Burnett A. K., Wheatley K., Goldstone A. H., Stevens R., Hann I., Rees J. K. & Gray R. G. (1994) Allogenic BMT in AML 10: is having a matched donor an advantage? Br. J. Haemat. 86 (Suppl. 1), 8.
26. Tsukihashi H., Nakanishi A., Matsuda H., Uejima S. & Kurita T. (1991) Cell proliferation of human bladder tumours determined by BrdUrd and Ki67 immunostaining. J. Urol. 145, 846.
27. Raillo M., Nordling S., Boguslawsky K. von, Leiovonen M., Kyllonen L. & Smitten K. von (1993) Prognostic value of Ki67 immunolabelling in primary operable breast cancer. Br. J. Cancer 68, 579.
28. Gerdes J. (1990) Ki-67 and other proliferation markers useful for immunohistological diagnostic and prognostic evaluations in human malignancies. Sem. Cancer Biol. 1, 199.
29. Reise W. T. W. de, Crabtree W. N., Allhoff E. P., Werner M., Liedke S., Lenis G., Atzpodien J. & Kirchner H. (1993) Prognostic significance of Ki-67 immunostaining in nonmetastatic renal carcinoma. J. clin. Oncol. 11, 1804.
30. Pope J., Ball L. M., Hayes S., Eccles P., Clapham E. M., McGill F., Howard C. V. & Velzen D. van (1994) Limitation of Ki 67 defined proliferation rates of malignant and non malignant cells in the bone marrow microenvironment. Br. J. Haemat. 86 (Suppl. 1), 46.
31. Elgie A. W., Sargent J. M. & Taylor C. G. In vitro study of PKC modulators in acute myeloid leukemia. In Advances in Blood Disorders. Harwood Academic (in press).
32. Sargent J., Taylor C. & Elgie A. (1993) Study of drug combinations in acute myeloid leukemia (AML) using the MTT assay. In Drug Resistance in Leukemia and Lymphoma: The Clinical Value of Laboratory Studies (Kaspers G. J. L., Pieters R., Twentyman P. R., Weisenthal L. M. & Veerman A. J. P., Eds), p. 292. Harwood Academic, Chur, Switzerland.